Matinas BioPharma has received an additional notice from the NYSE American for failing to meet the stockholders' equity requirement of at least $4 million after reporting losses in three of its four most recent fiscal years. The company had stockholders' equity of $3.02 million as of March 31, 2026, and has incurred losses in the five most recent fiscal years. This follows an earlier notice in April 2026 for not meeting the $6 million minimum equity threshold for companies with losses in five consecutive years. The NYSE has accepted Matinas' compliance plan, granting a plan period through October 2, 2027, during which the company can maintain its listing while undergoing quarterly monitoring. If compliance is not regained by the end of the plan period, delisting proceedings may begin.
Matinas BioPharma Holdings IncCompany received NYSE non-compliance notice for failing stockholders' equity requirement due to continued losses, with delisting risk if not resolved by October 2027.